Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
4.840
-0.120 (-2.42%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Bolt Biotherapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Bolt Biotherapeutics stock have an average target of 34, with a low estimate of 7.00 and a high estimate of 75. The average target predicts an increase of 602.48% from the current stock price of 4.84.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Bolt Biotherapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +44.63% | Mar 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +44.63% | Oct 20, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $4 → $75 | Strong Buy | Maintains | $4 → $75 | +1,449.59% | Aug 15, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +1,552.89% | May 20, 2025 |
| Stifel | Stifel | Hold Maintains $25 → $20 | Hold | Maintains | $25 → $20 | +313.22% | May 13, 2025 |
Financial Forecast
Revenue This Year
3.06M
from 7.70M
Decreased by -60.23%
Revenue Next Year
7.14M
from 3.06M
Increased by 133.33%
EPS This Year
-21.85
from -17.85
EPS Next Year
-40.39
from -21.85
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.3M | 7.4M | |||
| Avg | 3.1M | 7.1M | |||
| Low | n/a | 6.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -18.1% | 140.2% | |||
| Avg | -60.2% | 133.3% | |||
| Low | - | 124.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -10.02 | -41.58 | |||
| Avg | -21.85 | -40.39 | |||
| Low | -32.63 | -38.81 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.